Tegsedi (inotersen, Akcea™ Therapeutics)
Indications: Adult Patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Dosage: 284 mg adminstered by subcutaneous injection 1x weekly
Contraindications
FDA Approves Aprocitentan For Treatment of Uncontrolled High Blood Pressure
March 20th 2024Aprocitentan (TRYVIO) from pharmaceutical company Idorsia demonstrated statistically significant and clinically meaningful reductions in blood pressure in combination with other antihypertensive therapies.